Boehringer Ingelheim Receives APHIS Approval on new Circovirus Vaccine
US - Boehringer Ingelheim Vetmedica, Inc., (BIVI) has announced that it has received approval from the U.S. Animal and Plant Health Inspection Service for a new vaccine called Ingelvac® CircoFLEX™ to protect swine against diseases caused by porcine circovirus type 2 (PCV2).by the Iowa Department of Natural Resources.
25 October 2006
2 minute read
According to Klaas Okkinga, marketing manager for BIVI, Ingelvac CircoFLEX is a single-dose, 1 ml vaccine that provides the highest level of efficacy and safety to pigs.
“It’s highly effective in immunizing pigs as young as 3 weeks of age prior to exposure to PCV2, and provides long-lasting protection without the systemic irritation and tissue reactions some vaccines can cause.”
In addition, Ingelvac CircoFLEX has a short 21-day withdrawal period and positive pork quality assurance benefits that are important to producers, Okkinga adds.
“It has been thoroughly field tested and we are confident this vaccine will help producers more effectively prevent porcine circovirus associated disease.”
Ingelvac CircoFLEX will be widely available to US producers in 2007.
“It’s highly effective in immunizing pigs as young as 3 weeks of age prior to exposure to PCV2, and provides long-lasting protection without the systemic irritation and tissue reactions some vaccines can cause.”
In addition, Ingelvac CircoFLEX has a short 21-day withdrawal period and positive pork quality assurance benefits that are important to producers, Okkinga adds.
“It has been thoroughly field tested and we are confident this vaccine will help producers more effectively prevent porcine circovirus associated disease.”
Ingelvac CircoFLEX will be widely available to US producers in 2007.
